Published in Clin Med Res on March 01, 2006
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J (2007) 1.10
Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort. Parasite Immunol (2010) 0.97
Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children. Clin Vaccine Immunol (2011) 0.93
Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria. Malar J (2014) 0.82
Evaluation of allelic forms of the erythrocyte binding antigen 175 (EBA-175) in Plasmodium falciparum field isolates from Brazilian endemic area. Malar J (2011) 0.77
Antibody response against three Plasmodium falciparum merozoite antigens in Mamuju District, West Sulawesi Province, Indonesia. Malar J (2014) 0.75
Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. PLoS One (2017) 0.75
Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science (1994) 5.81
Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med (1998) 5.41
Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol (1974) 5.22
Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med (1990) 5.04
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Med Hyg (1990) 4.70
A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science (1985) 4.28
Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun (1992) 3.42
Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today (1993) 3.28
Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol (1992) 3.12
Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol (1990) 3.11
Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today (1995) 3.00
Determination of genetic variation within Plasmodium falciparum by using enzymatically amplified DNA from filter paper disks impregnated with whole blood. J Clin Microbiol (1991) 2.82
Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion. Proc Natl Acad Sci U S A (2000) 2.76
Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun (1995) 2.48
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg (1998) 2.41
Plasmodium falciparum field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A. Infect Immun (1999) 2.37
A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha 2-3)Gal- sequences of glycophorin A. J Cell Biol (1992) 2.19
Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg (1996) 1.98
Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol Lett (2000) 1.89
Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun (2000) 1.77
High immunoglobulin G2 (IgG2) and low IgG4 levels are associated with human resistance to Plasmodium falciparum malaria. Infect Immun (2000) 1.73
Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun (2000) 1.66
Aspects of the molecular structure of IgG subclasses. Monogr Allergy (1986) 1.56
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis (2000) 1.48
A hypothesis about the chronicity of malaria infection. Parasitol Today (1997) 1.47
Allelic diversity and antibody recognition of Plasmodium falciparum merozoite surface protein 1 during hypoendemic malaria transmission in the Brazilian amazon region. Infect Immun (1999) 1.40
Two alleles of the 175-kilodalton Plasmodium falciparum erythrocyte binding antigen. Mol Biochem Parasitol (1993) 1.35
Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg (1994) 1.30
Comparison of immunity to malaria in Sudan and Indonesia: crisis-form versus merozoite-invasion inhibition. Proc Natl Acad Sci U S A (1984) 1.28
Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol (1995) 1.26
Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form. Mol Biochem Parasitol (1992) 1.20
Relationships between maternal malaria and malarial immune responses in mothers and neonates. Parasite Immunol (1995) 1.13
Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies. Infect Immun (1997) 1.07
Sequence conservation of a functional domain of erythrocyte binding antigen 175 in Plasmodium falciparum. Mol Biochem Parasitol (1990) 1.02
Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans R Soc Trop Med Hyg (2000) 1.02
EBA-175: an erythrocyte-binding ligand of Plasmodium falciparum. Parasitol Today (1995) 1.01
Immune responses against Plasmodium falciparum asexual blood-stage antigens and disease susceptibility in Gabonese and Cameroonian children. Am J Trop Med Hyg (1999) 1.01
Identification of an erythrocyte binding peptide from the erythrocyte binding antigen, EBA-175, which blocks parasite multiplication and induces peptide-blocking antibodies. Infect Immun (1998) 0.90
Relationships between malaria prevalence and malaria-related morbidity in school children from two villages in central Africa. Am J Trop Med Hyg (1999) 0.88
Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Malar J (2008) 2.16
High level of var2csa transcription by Plasmodium falciparum isolated from the placenta. J Infect Dis (2005) 1.90
Congenital parasitic infections: a review. Acta Trop (2011) 1.88
Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in Benin. Am J Trop Med Hyg (2011) 1.80
Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog (2006) 1.76
Population genomics of the immune evasion (var) genes of Plasmodium falciparum. PLoS Pathog (2007) 1.74
Do African immigrants living in France have long-term malarial immunity? Am J Trop Med Hyg (2005) 1.39
Variable adhesion abilities and overlapping antigenic properties in placental Plasmodium falciparum isolates. J Infect Dis (2004) 1.36
Can treatment of malaria be restricted to parasitologically confirmed malaria? A school-based study in Benin in children with and without fever. Malar J (2010) 1.36
Dramatically decreased therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine, but not mefloquine, in southern Benin. Trop Med Int Health (2007) 1.30
PfHRP2 and PfLDH antigen detection for monitoring the efficacy of artemisinin-based combination therapy (ACT) in the treatment of uncomplicated falciparum malaria. Malar J (2009) 1.29
The role of the G6PD AEth376G/968C allele in glucose-6-phosphate dehydrogenase deficiency in the seerer population of Senegal. Haematologica (2006) 1.26
Combination of drug level measurement and parasite genotyping data for improved assessment of amodiaquine and sulfadoxine-pyrimethamine efficacies in treating Plasmodium falciparum malaria in Gabonese children. Antimicrob Agents Chemother (2003) 1.24
The sickle cell trait is associated with enhanced immunoglobulin G antibody responses to Plasmodium falciparum variant surface antigens. J Infect Dis (2005) 1.23
Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J (2011) 1.21
Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin. Am J Trop Med Hyg (2011) 1.21
Plasmodium falciparum genotype population dynamics in asymptomatic children from Senegal. Microbes Infect (2006) 1.18
In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooué region of Gabon. J Antimicrob Chemother (2003) 1.17
DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother (2003) 1.16
Polymorphism in two merozoite surface proteins of Plasmodium falciparum isolates from Gabon. Malar J (2003) 1.15
Infections in infants during the first 12 months of life: role of placental malaria and environmental factors. PLoS One (2011) 1.12
IL-12 producing monocytes and IFN-gamma and TNF-alpha producing T-lymphocytes are increased in placentas infected by Plasmodium falciparum. J Reprod Immunol (2006) 1.12
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Relation between Plasmodium falciparum asymptomatic infection and malaria attacks in a cohort of Senegalese children. Malar J (2008) 1.07
First-trimester Plasmodium falciparum infections display a typical "placental" phenotype. J Infect Dis (2012) 1.07
Maternally transmitted antibodies to pregnancy-associated variant antigens on the surface of erythrocytes infected with Plasmodium falciparum: relation to child susceptibility to malaria. Am J Epidemiol (2003) 1.06
Malaria, from natural to supernatural: a qualitative study of mothers' reactions to fever (Dienga, Gabon). J Epidemiol Community Health (2004) 1.05
Demonstration of a high level of parasite population homology by quantification of Plasmodium falciparum alleles in matched peripheral, placental, and umbilical cord blood samples. J Clin Microbiol (2005) 1.05
First malaria infections in a cohort of infants in Benin: biological, environmental and genetic determinants. Description of the study site, population methods and preliminary results. BMJ Open (2012) 1.04
Expression of the domain cassette 8 Plasmodium falciparum erythrocyte membrane protein 1 is associated with cerebral malaria in Benin. PLoS One (2013) 1.03
The NTS-DBL2X region of VAR2CSA induces cross-reactive antibodies that inhibit adhesion of several Plasmodium falciparum isolates to chondroitin sulfate A. J Infect Dis (2011) 1.02
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J (2013) 1.01
Role of environment and behaviour in familial resemblances of Plasmodium falciparum infection in a population of Senegalese children. Microbes Infect (2004) 1.00
Association of haptoglobin levels with age, parasite density, and haptoglobin genotype in a malaria-endemic area of Gabon. Am J Trop Med Hyg (2006) 1.00
Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies. Vaccine (2012) 1.00
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med (2015) 0.99
A molecular epidemiological study of var gene diversity to characterize the reservoir of Plasmodium falciparum in humans in Africa. PLoS One (2011) 0.98
Impact of red blood cell polymorphisms on the antibody response to Plasmodium falciparum in Senegal. Microbes Infect (2006) 0.97
Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, Benin. Emerg Infect Dis (2015) 0.96
Plasmodium falciparum exposure in utero, maternal age and parity influence the innate activation of foetal antigen presenting cells. Malar J (2009) 0.96
Influence of carriage of hemoglobin AS and the Fc gamma receptor IIa-R131 allele on levels of immunoglobulin G2 antibodies to Plasmodium falciparum merozoite antigens in Gabonese children. J Infect Dis (2005) 0.96
Differential evolution of anti-VAR2CSA- IgG3 in primigravidae and multigravidae pregnant women infected by Plasmodium falciparum. Malar J (2008) 0.96
Plasmodium falciparum transcriptome analysis reveals pregnancy malaria associated gene expression. PLoS One (2008) 0.96
Consequences of gestational malaria on birth weight: finding the best timeframe for intermittent preventive treatment administration. PLoS One (2012) 0.95
Sickle cell trait carriage: imbalanced distribution of IgG subclass antibodies reactive to Plasmodium falciparum family-specific MSP2 peptides in serum samples from Gabonese children. Immunol Lett (2002) 0.95
Plasmodium vivax malaria during pregnancy, Bolivia. Emerg Infect Dis (2013) 0.93
Reliability of rapid diagnostic tests in diagnosing pregnancy-associated malaria in north-eastern Tanzania. Malar J (2012) 0.93
Biomarkers of Plasmodium falciparum infection during pregnancy in women living in northeastern Tanzania. PLoS One (2012) 0.93
Malaria modifies neonatal and early-life toll-like receptor cytokine responses. Infect Immun (2013) 0.92
Monocyte activation and T cell inhibition in Plasmodium falciparum-infected placenta. J Infect Dis (2004) 0.92
Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria. Infect Genet Evol (2006) 0.92
Malaria associated symptoms in pregnant women followed-up in Benin. Malar J (2011) 0.92
Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin. Antimicrob Agents Chemother (2013) 0.91
The imprint of the Slave Trade in an African American population: mitochondrial DNA, Y chromosome and HTLV-1 analysis in the Noir Marron of French Guiana. BMC Evol Biol (2010) 0.91
High prevalence of Plasmodium falciparum pfcrt K76T mutation in pregnant women taking chloroquine prophylaxis in Senegal. J Antimicrob Chemother (2005) 0.90
Acquisition of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes during pregnancy. Infect Genet Evol (2006) 0.90
Plasmodium falciparum population dynamics in a cohort of pregnant women in Senegal. Malar J (2010) 0.89
Genome wide linkage study, using a 250K SNP map, of Plasmodium falciparum infection and mild malaria attack in a Senegalese population. PLoS One (2010) 0.88
Short report: lack of prediction of amodiaquine efficacy in treating Plasmodium falciparum malaria by in vitro tests. Am J Trop Med Hyg (2004) 0.88
What would PCR assessment change in the management of fevers in a malaria endemic area? A school-based study in Benin in children with and without fever. Malar J (2010) 0.88
Association of HLA-G 3'UTR polymorphisms with response to malaria infection: a first insight. Infect Genet Evol (2013) 0.87
Analysis of IgG with specificity for variant surface antigens expressed by placental Plasmodium falciparum isolates. Malar J (2004) 0.86
Insight into antigenic diversity of VAR2CSA-DBL5ε domain from multiple Plasmodium falciparum placental isolates. PLoS One (2010) 0.86
Receptor-binding studies of the DBLgamma domain of Plasmodium falciparum erythrocyte membrane protein 1 from a placental isolate. Mol Biochem Parasitol (2006) 0.86
Impact of pregnancy-associated malaria on infant malaria infection in southern Benin. PLoS One (2013) 0.86
Towards the rational design of a candidate vaccine against pregnancy associated malaria: conserved sequences of the DBL6epsilon domain of VAR2CSA. PLoS One (2010) 0.85
Molecular aspects of Plasmodium falciparum Infection during pregnancy. J Biomed Biotechnol (2007) 0.85
Malaria and gravidity interact to modify maternal haemoglobin concentrations during pregnancy. Malar J (2012) 0.85
Distribution of IgG subclass antibodies specific for Plasmodium falciparum glutamate-rich-protein molecule in sickle cell trait children with asymptomatic infections. Exp Parasitol (2005) 0.85
Peripheral blood cell signatures of Plasmodium falciparum infection during pregnancy. PLoS One (2012) 0.84
G6PD A-variant influences the antibody responses to Plasmodium falciparum MSP2. Infect Genet Evol (2011) 0.84
Mass spectrometry detection of G3m and IGHG3 alleles and follow-up of differential mother and neonate IgG3. PLoS One (2012) 0.84
Functional and immunological characterization of a duffy binding-like- gamma domain from Plasmodium falciparum erythrocyte membrane protein-1 expressed by a placental isolate. J Infect Dis (2005) 0.84
Functional and immunological characterization of the var2CSA-DBL5epsilon domain of a placental Plasmodium falciparum isolate. Mol Biochem Parasitol (2010) 0.84
Family analysis of malaria infection in Dienga, Gabon. Am J Trop Med Hyg (2002) 0.83
Cellular immune response to Plasmodium falciparum after pregnancy is related to previous placental infection and parity. Malar J (2002) 0.83
Association of IL-4 and IL-10 maternal haplotypes with immune responses to P. falciparum in mothers and newborns. BMC Infect Dis (2013) 0.82
Differential adhesion-inhibitory patterns of antibodies raised against two major variants of the NTS-DBL2X region of VAR2CSA. Vaccine (2013) 0.82
In vitro activity of chloroquine, quinine, mefloquine and halofantrine against Gabonese isolates of Plasmodium falciparum. Trop Med Int Health (2003) 0.82
Prevalence and factors related to antibiotic prescription in Benin: a school-based study. Acta Trop (2013) 0.81
Placental malaria-associated suppression of parasite-specific immune response in neonates has no major impact on systemic CD4 T cell homeostasis. Infect Immun (2011) 0.81
Temporal variations in immune responses to conserved regions of Plasmodium falciparum merozoite surface proteins related to the severity of a prior malaria episode in Gabonese children. Trans R Soc Trop Med Hyg (2004) 0.81
The humoral response to Plasmodium falciparum VarO rosetting variant and its association with protection against malaria in Beninese children. Malar J (2010) 0.81
Development of cellular immune responses to Plasmodium falciparum blood stage antigens from birth to 36 months of age in Cameroon. Acta Trop (2006) 0.80
Epistatic Interactions between apolipoprotein E and hemoglobin S Genes in regulation of malaria parasitemia. PLoS One (2013) 0.80
Plasma and in vitro levels of cytokines during and after a Plasmodium falciparum malaria attack in Gabon. Acta Trop (2002) 0.80
Structural and immunological correlations between the variable blocks of the VAR2CSA domain DBL6ε from two Plasmodium falciparum parasite lines. J Mol Biol (2013) 0.79
Gestational age-related changes in the peripheral blood cell composition of sub-Saharan African women. J Reprod Immunol (2013) 0.79